Akero Rebounds as Benefit Deepens in Key Mid-Stage MASH Trial
After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed greater improvements after 96 weeks of treatment in an advanced disease population.
Akero Rebounds as Benefit Deepens in Key Mid-Stage MASH Trial Read More »
